Similar articles for PMID: 25759591

Year	Number of Results
2003	1
2010	2
2012	2
2013	2
2014	1
2015	4
2016	2
2017	3
2018	5
2019	7
2020	2
2021	5
2022	1
2023	1
2024	0

1

Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes.

Powell DR, Doree D, Jeter-Jones S, Ding ZM, Zambrowicz B, Sands A. Powell DR, et al. Diabetes Metab Syndr Obes. 2015 Feb 26;8:121-7. doi: 10.2147/DMSO.S76342. eCollection 2015. Diabetes Metab Syndr Obes. 2015. PMID: 25759591 Free PMC article.

2

Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study.

Bode BW, Cengiz E, Wadwa RP, Banks P, Danne T, Kushner JA, McGuire DK, Peters AL, Strumph P, Sawhney S. Bode BW, et al. Diabetes Technol Ther. 2021 Jan;23(1):59-69. doi: 10.1089/dia.2020.0079. Diabetes Technol Ther. 2021. PMID: 32640846 Free PMC article. Clinical Trial.

3

Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.

Danne T, Cariou B, Buse JB, Garg SK, Rosenstock J, Banks P, Kushner JA, McGuire DK, Peters AL, Sawhney S, Strumph P. Danne T, et al. Diabetes Care. 2019 May;42(5):919-930. doi: 10.2337/dc18-2149. Epub 2019 Mar 4. Diabetes Care. 2019. PMID: 30833371 Free PMC article.

4

Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.

Danne T, Biester T, Kordonouri O. Danne T, et al. Diabetes Technol Ther. 2018 Jun;20(S2):S269-S277. doi: 10.1089/dia.2018.0081. Diabetes Technol Ther. 2018. PMID: 29916741

5

A review of sotagliflozin for use in type 1 diabetes.

Nuffer W, Williams B, Trujillo JM. Nuffer W, et al. Ther Adv Endocrinol Metab. 2019 Nov 26;10:2042018819890527. doi: 10.1177/2042018819890527. eCollection 2019. Ther Adv Endocrinol Metab. 2019. PMID: 31807264 Free PMC article. Review.

6

Sotagliflozin as a potential treatment for type 2 diabetes mellitus.

Cariou B, Charbonnel B. Cariou B, et al. Expert Opin Investig Drugs. 2015;24(12):1647-56. doi: 10.1517/13543784.2015.1100361. Epub 2015 Nov 7. Expert Opin Investig Drugs. 2015. PMID: 26548423 Review.

7

Sotagliflozin: A Review in Type 1 Diabetes.

Deeks ED. Deeks ED. Drugs. 2019 Dec;79(18):1977-1987. doi: 10.1007/s40265-019-01230-w. Drugs. 2019. PMID: 31761990 Review.

8

Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone.

Danne T, Joish VN, Afonso M, Banks P, Sawhney S, Lapuerta P, Davies MJ, Buse JB, Lin D, Reaney M, Guillonneau S, Snoek FJ, Bailey TS, Polonsky WH. Danne T, et al. Diabetes Technol Ther. 2021 Jan;23(1):70-77. doi: 10.1089/dia.2020.0068. Diabetes Technol Ther. 2021. PMID: 32721228 Clinical Trial.

9

Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus.

Sims H, Smith KH, Bramlage P, Minguet J. Sims H, et al. Diabet Med. 2018 Aug;35(8):1037-1048. doi: 10.1111/dme.13645. Epub 2018 Jul 3. Diabet Med. 2018. PMID: 29637608 Review.

10

Efficacy and safety of sotagliflozin in treating diabetes type 1.

Rendell MS. Rendell MS. Expert Opin Pharmacother. 2018 Feb;19(3):307-315. doi: 10.1080/14656566.2017.1414801. Epub 2017 Dec 29. Expert Opin Pharmacother. 2018. PMID: 29212386 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

34 results

Results by year